Oncologists Spend Too Little Time With Patients, Too Much on EHR
The Medscape Oncologist Compensation Report 2018 reveals more about oncology practice than simple dollars and cents. (Source: Medscape Oncology)
Source: Medscape Oncology - April 26, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Neoadjuvant Immunotherapy Data Suggest More Lung Cancer Cures
Among the new data on immunotherapy for lung cancer presented at the recent AACR meeting, the potential role of immune checkpoint inhibitors in the neoadjuvant setting may be the most promising. (Source: Medscape Oncology)
Source: Medscape Oncology - April 26, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Checkpoint Inhibitors Have a Role for 'Virtually Every Patient'
After an'extraordinary week'of advances in lung cancer, Dr Mark Kris explains why checkpoint inhibitors now play a major role in lung cancer therapy. (Source: Medscape Oncology)
Source: Medscape Oncology - April 25, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

'Oncology Done Right Is About Balance': Weighing IO Side Effects
When discussing checkpoint inhibitor adverse effects, Dr Mark Kris argues that we have to consider their potentially outsize benefits. (Source: Medscape Oncology)
Source: Medscape Oncology - April 23, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Stop Screening for Early Ovarian Cancer, USPSTF Says
There is no evidence that screening actually improves outcomes in ovarian cancer, according to a USPSTF analysis of the best available data. (Source: Medscape Oncology)
Source: Medscape Oncology - April 13, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

'100,000 Genomes' Project: Linking Genome Sequencing to Outcomes
Dr David Kerr shares thoughts on the 100,000 Genomes project linking whole genome sequencing to outcomes and the skepticism among some colleagues about the benefits of so-called actionable mutations. (Source: Medscape Oncology)
Source: Medscape Oncology - April 10, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

An Alternative to Dalteparin for Cancer-Related VTE
Dr David Kerr discusses a promising new study suggesting that oral edoxaban may be substituted for daily subcutaneous dalteparin in cancer patients who have had a venous thromboembolism. (Source: Medscape Oncology)
Source: Medscape Oncology - April 2, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Is Genotype Screening Needed Before Fluoropyrimidines?
Dr David Kerr on how the recent case for DPYD screening may be on (and off) mark in addressing chemotherapy toxicity. (Source: Medscape Oncology)
Source: Medscape Oncology - March 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

A Moment to Reflect on Communicating Bad News to Patients
Dr David J. Kerr discusses the difficult task of delivering bad news to patients--and their often paradoxical response--by sharing one of his favorite poems by Raymond Carver (Source: Medscape Oncology)
Source: Medscape Oncology - March 13, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Combined Prognostic Factors Clarify Colorectal Cancer Risk
Dr David Kerr on how combining ploidy and stroma-tumor fraction can guide treatment decisions in patients with stage II disease. (Source: Medscape Oncology)
Source: Medscape Oncology - March 12, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Survey: Stark Disparities Exist in Global Oncologists' Workload
Dr David Kerr on a first-of-its-kind analysis revealing that much work is needed to alleviate the burden on colleagues worldwide. (Source: Medscape Oncology)
Source: Medscape Oncology - March 9, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

'False Hope' Over Immunotherapy? The Media's Misguided Effects
Dr Kathy Miller responds to a recentNew York Timesarticle documenting rare immunotherapy responses, which may lead to false hope among cancer patients and their families. (Source: Medscape Oncology)
Source: Medscape Oncology - March 6, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

'Tremendous Loss' of a Giant in Psycho-Oncology
Dr Mark Kris pays tribute to a true giant in the field of oncology and his dear friend, Jimmie Holland. (Source: Medscape Oncology)
Source: Medscape Oncology - March 5, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Is Aspirin the New (Old) Immunotherapy?
Dr David Kerr on how this time-tested drug enhances more complex and expensive immunotherapies. (Source: Medscape Oncology)
Source: Medscape Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Lower-Dose Combo Immunotherapy Promising for Advanced Melanoma
Dr Jeffrey S. Weber reviews data from an open-label phase 1/2 trial assessing the efficacy and safety of combination pembrolizumab and reduced-dose ipilimumab in patients with advanced melanoma. (Source: Medscape Oncology)
Source: Medscape Oncology - February 22, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

'Moving the Needle' in Oncology Workforce Diversity
Authors of a recent ASCO statement on diversity discuss their experiences and suggestions for improving inclusivity in the oncology workforce. (Source: Medscape Oncology)
Source: Medscape Oncology - February 22, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Feb 16, 2018 This Week in Cardiology
ICD use in patients with CKD, PFO and peri-operative stroke, LV assist devices, guideline-directed medical therapy after revascularization, and upcoming trials in 2018 are discussed in this week's podcast. (Source: Medscape Oncology)
Source: Medscape Oncology - February 16, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Overlooked Biomarker May Predict Cancer Immunotherapy Response
Dr David Kerr on data showing that tumors with extensive aneuploidy may not benefit as much from immune checkpoint blockade. (Source: Medscape Oncology)
Source: Medscape Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Beyond APHINITY: What Now After Pivotal Breast Cancer Trial?
Dr Kathy Miller speaks with APHINITY's principal investigator about whether survival in HER2+ disease can be pushed even further. (Source: Medscape Oncology)
Source: Medscape Oncology - February 15, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Selective Internal Radiotherapy Fails Again in mCRC
Dr David Kerr on the latest setback from this once promising therapy. (Source: Medscape Oncology)
Source: Medscape Oncology - February 9, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

IDEA Trial Remakes Adjuvant Chemo in Colorectal Cancer
Dr David Kerr on how one of the biggest studies at ASCO is already changing practice. (Source: Medscape Oncology)
Source: Medscape Oncology - February 9, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

FDA Again Advises Against Morcellators for Fibroids
The risk for uterine sarcoma being found in fibroids is too high, notes Dr Markman. (Source: Medscape Oncology)
Source: Medscape Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

An Exceptional Case: IL-17 and Immune Checkpoint Inhibition
A case report suggests that IL-17 plays an important role in immune checkpoint inhibition, argues Dr David Kerr. (Source: Medscape Oncology)
Source: Medscape Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Infection Prophylaxis, Immune Therapies Lead ASH Myeloma Data
Dr S. Vincent Rajkumar discusses the most promising new treatments reported for multiple stages of myeloma at this year's ASH meeting. (Source: Medscape Oncology)
Source: Medscape Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Why Do Physicians Overtreat Elderly Breast Cancer Patients?
Drs Kathy Miller and Reshma Jagsi on the reasons behind practitioners'reluctance to omit radiation therapy in older patients. (Source: Medscape Oncology)
Source: Medscape Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Practice-Changing Regorafenib Data at 2018 GI Cancers Symposium
Dr John Marshall discusses new science in pancreatic and colorectal cancers, presented at the 2018 Gastrointestinal Cancers Symposium. (Source: Medscape Oncology)
Source: Medscape Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Celebrating the End of Chemo Can Isolate Those Not So Lucky
Dr John Marshall on how a recent symposium opened his eyes to the unintended effects of a bell-ringing ceremony at his practice. (Source: Medscape Oncology)
Source: Medscape Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

ESMO Survey Data Clarify Gender Differences in Oncology
Leaders from the European Society for Medical Oncology discuss survey data on gender gaps in oncology and propose solutions to close these gaps between men and women professionally. (Source: Medscape Oncology)
Source: Medscape Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Costly Rare Cancer Drugs Fund Fails to Provide Clinical Benefit
Set up to improve access to anti-cancer orphan drugs, the CDF did not live up to its promise, says Dr Kerr. (Source: Medscape Oncology)
Source: Medscape Oncology - January 30, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Comparing CAR T-Cell Therapies in Lymphoma
Drs Ann LaCasce and Caron Jacobson on how these and other treatments may change your practice in the new year. (Source: Medscape Oncology)
Source: Medscape Oncology - January 29, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Maximizing Response in Acute Leukemia: Pearls From ASH 2017
Drs Cortes and DeAngelo highlight the most intriguing clinical trials presented in the field of leukemia at ASH 2017. (Source: Medscape Oncology)
Source: Medscape Oncology - January 29, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

The Four Studies That Changed Thoracic Oncology in 2017
Dr Mark Kris on how 2017 clarified the importance of achieving progression-free survival in lung cancer patients. (Source: Medscape Oncology)
Source: Medscape Oncology - January 25, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

More Intense Neoadjuvant ECX Regimen Fails for Esophageal Cancer
Dr Kerr reports on a large, well-designed trial with disappointing results. (Source: Medscape Oncology)
Source: Medscape Oncology - January 25, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Oral HPV Infection Rate Is Alarmingly High in US Men
A large population-based study argues for more rigorous efforts to vaccinate against HPV infection and prevent subsequent head and neck cancers, says Dr Markman. (Source: Medscape Oncology)
Source: Medscape Oncology - January 25, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

'Cultural Change' in DCIS
Some think it's time to change how we talk about DCIS and to consider de-escalation of therapy. Drs Kathy Miller and Shelley Hwang discuss these hot topics and the COMET study at SABCS 2017. (Source: Medscape Oncology)
Source: Medscape Oncology - January 17, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers
Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy. (Source: Medscape Oncology)
Source: Medscape Oncology - January 17, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

New GI Cancer Studies: Curious Failures, Hidden Gems
Dr John Marshall on recent publications, both positive and negative, that may change your practice. (Source: Medscape Oncology)
Source: Medscape Oncology - January 3, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Will Immunotherapy Be a PANACEA for Breast Cancer?
Drs Kathy Miller and Sherene Loi discuss advances in immunotherapy for breast cancer, particularly in HER2-positive disease and TNBC. (Source: Medscape Oncology)
Source: Medscape Oncology - January 2, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab. (Source: Medscape Oncology)
Source: Medscape Oncology - December 29, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Seeking Consensus Amid Abundant New Lung Cancer Data
Dr Mark Kris on the big take-away lessons from the recent New York Lung Cancers Symposium. (Source: Medscape Oncology)
Source: Medscape Oncology - December 28, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Does Breast Cancer Risk REACT to Celecoxib?
Does this COX-2 inhibitor alter breast cancer risk? Dr Kathy Miller discusses the results of the REACT trial with its primary investigator, Dr Charles Coombes. (Source: Medscape Oncology)
Source: Medscape Oncology - December 27, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Clear Path to Reducing Cancer Risk in China
Dr David Kerr describes an epidemiologic study that found three standout risk factors for cancer in Chinese men and women. (Source: Medscape Oncology)
Source: Medscape Oncology - December 21, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Oncologists Need to Encourage Their Patients to Exercise
Even a brief conversation about exercise can reap significant health benefits to patients, argues Dr Markman. (Source: Medscape Oncology)
Source: Medscape Oncology - December 18, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Chemotherapy or Palliative Care: How to Decide?
The sign of a mature oncologist is knowing when not to treat someone, says Dr Kerr. A new tool may bolster that knowledge. (Source: Medscape Oncology)
Source: Medscape Oncology - December 15, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Hormonal Therapy in Advanced Endometrial Cancer
This meta-analysis may finally clarify which patients are most likely to respond to hormonal therapy. (Source: Medscape Oncology)
Source: Medscape Oncology - December 15, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Hot Topics (and Hot Chilis): SABCS 2017
Dr Kathy Miller highlights potential practice-changing studies that she is looking forward to at SABCS 2017. (Source: Medscape Oncology)
Source: Medscape Oncology - December 5, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Epacadostat + Pembro for Melanoma: Beneficial, Well Tolerated
This combination produced impressive response and disease control rates with good tolerability in treatment-naive patients with advanced melanoma. (Source: Medscape Oncology)
Source: Medscape Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Prostate Cancer Care Is 'Changing Rapidly': ESMO 2017
Exciting research presented at ESMO 2017 will likely affect clinical practice in metastatic prostate cancer, says Dr Johann de Bono. (Source: Medscape Oncology)
Source: Medscape Oncology - November 17, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Improved Insurance Access Increases Elective Colon Resection Rates
A new analysis proves that the Massachusetts health insurance'experiment'resulted in better cancer care. (Source: Medscape Oncology)
Source: Medscape Oncology - November 16, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Stage III CRC: Which Patients Need 6 Months of Adjuvant Chemo?
At the ESMO 2017 Congress in Madrid, Drs Sobrero and Taieb discuss the optimal duration of adjuvant chemotherapy for stage III colon cancer. (Source: Medscape Oncology)
Source: Medscape Oncology - November 16, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts